The anti-ErbB3 mAb, CDX-3379, previously demonstrated encouraging albeit preliminary anti-tumor activity in HPV-negative HNSCC [19,20,21]. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.